Science Tour Health Research in Germany December 4 -10, 2011 Participants

1 DENMARK “Research in Germany” Science Tour – “Health Research in Germany”

POLAND Our world is increasingly being shaped by a globalization process, driven by a knowl- HEIDELBERG STUTTGART MUNICH edge-based economy. Education and research have become powerful forces behind social, economic and cultural developments. The exchange of ideas and academic cooperation are the keys to our mutual welfare and economic growth. In recognition of THE this, the German Federal Government is increasing its investments in research and devel- NETHER- opment and focusing more intensively on internationalizing key future sectors. LANDS European Molecular Fraunhofer Institute Ludwig Maximilians Biology Laboratory for Interfacial University Munich (EMBL) Engineering and (LMU) On the occasion of the Year of Science 2011 “Research for Our Health,” launched Biotechnology (IGB) by the Federal Ministry of Education and Research (BMBF), the German Academic Exchange Service (DAAD) has invited international scientists and administrators to learn more about medical research and graduate education in Germany. During a week- long tour, they will become acquainted with Germany’s unique network of university German Cancer Max Planck and non-university research institutes and their close ties to industry and commerce. The Research Center Institute of program will focus on three highly topical issues in healthcare today: personalized (DKFZ) Biochemistry (MPIB) medicine, neurodegenerative diseases and cancer research.

BELGIUM TUEBINGEN The Science Tour 2011 is part of the “Research in Germany – Land of Ideas” campaign, initiated by the BMBF in 2006 to strengthen and expand R&D collaboration between Germany and international partners. The tour, organized by the DAAD on behalf of the Rinecker Proton BMBF, brings German and international researchers together to discuss current develop- Heidelberg Therapy Center ments in health research and to deﬁ ne common areas of interest as starting points for (RPTC) Hertie future cooperation. Institute for Clinical Brain Research CZECH (HIH) Stuttgart The DAAD is the largest funding organisation in the world and supports the international REPUBLIC exchange of students and scholars. Its primary objectives include encouraging outstand- Tuebingen PENZBERG ing academics from abroad to study or conduct research in Germany and enabling FRANCE Munich German researchers to gain professional qualiﬁ cation at the best institutions around the world. For more information on “Research in Germany”, the annual Science Tours and the DAAD, please visit:

Penzberg Roche Diagnostics • www.research-in-germany.de GmbH • www.research-in-germany.de/sciencetours SWITZERLAND AUSTRIA • www.daad.de Sunday, December 4, 2011 Monday, December 5, 2011 Arrival in Munich according to individual arrangements Round table discussion and coffee break Moderator Dr. Christian Schäfer Check-in at the Head of Section: Internationalisation of Research Rinecker Proton Therapy Center – RPTC Guesthouse German Academic Exchange Service 5:30 – 7:30 p.m. Welcome address and general introduction (room: 349) High-Tech Campus, guided tour of Gene Center Munich Dr. Christian Schäfer Prof. Dr. Eckhard Wolf Head of Section: Internationalisation of Research Director, Institute of Molecular Animal Breeding and German Academic Exchange Service Biotechnology Anne Knab Group 1: Dr. Helmut Blum Project Ofﬁ cer, Section: Marketing for Research Head of Genomics German Academic Exchange Service Laboratory for Functional Genome Analysis (LAFUGA) 7:30 p.m. Walk to the restaurant » Transcriptomics 7:45 – 9:15 p.m. Dinner at the restaurant Zum Flaucher Group 2: Dr. Georg J. Arnold Walk back to the guesthouse Head of Proteomics Laboratory for Functional Genome Analysis (LAFUGA) Program Program Accommodation RPTC Guesthouse, Munich » Proteomics

4 Further participants: 5

Monday, December 5, 2011 Dr. Isolde von Bülow Head of Graduate Center, LMU Munich 8:15 a.m. Transfer Dr. Robert Fürst 9:00 – 12:30 p.m. Biocenter, Ludwig Maximilians University of Munich – LMU Project Leader, Department of Pharmacy, LMU Munich Prof. Dr. Ulrich Pohl Prof. Dr. Olivier Gires Vice President, International Affairs Head of ENT Research and the Clinical Cooperation Group: Welcome and presentation of LMU Munich » Molecular Oncology, LMU Munich Prof. Dr. Patrick Cramer Dr. Matthias Hadesbeck Head of Gene Center Munich, Department of Biochemistry Acting Head of the International Ofﬁ ce, LMU Munich » Welcome Dr. Manfred Ogris Prof. Dr. Horst Domdey Group Leader: Vectorology, Department of Pharmacy, LMU Managing Director, BioM Biotech Cluster Development GmbH Munich » “m4 – Munich’s Integrated Approach to Personalized Medicine” Dr. Stephanie Wehnelt International Affairs & Training Prof. Dr. Georg Marckmann, MPH BioM Biotech Cluster Development GmbH Director, Institute of Ethics, History, and Theory of Medicine » “A New Paradigm with Old Challenges? Ethical Implications of Personalized Medicine” Monday, December 5, 2011 Monday, December 5, 2011 Dr. Karin Jacob Dr. Andreas Pichlmair Senior Project Manager m4 Head of the Max Planck Research Group: BioM Biotech Cluster Development GmbH Innate Immunity “Innate Immune Recognition and Stealth Dr. Daniela Tonn » Strategies of Viruses” Manager, International Affairs & Training BioM Biotech Cluster Development GmbH Coffee break Informal discussion 12:30 p.m. Transfer 5:30 – 6:00 p.m. Transfer (1st stop: city center, 2nd stop: hotel) 12:45 p.m. Lunch at Café Freshmaker 7:00 p.m. Transfer 1:40 p.m. Transfer 7:30 – 9:00 p.m. Dinner at the restaurant Hofer – Der Stadtwirt 2:00 – 5:30 p.m. Max Planck Institute of Biochemistry – MPIB Transfer Dr. Ralf Tatzel Assistant to the Board of Managing Directors Accommodation RPTC Guesthouse, Munich » Presentation of the Max Planck Institute of Biochemistry Dr. Andreas Bracher and Dr. Mark Hipp Program Program Program Project Group Leaders Tuesday, December 6, 2011 Research Department: Cellular Biochemistry 6 Checkout 7 “Protein Folding in Health and Disease” » 8:15 a.m. Walk to RPTC Parallel guided lab tours: 8:30 – 9:45 a.m. Rinecker Proton Therapy Center – RPTC Group 1: Prof. Dr. Manfred Herbst Dr. Zuzana Storchova Medical Director Head of the Max Planck Research Group: Medical Executive Board, PROHEALTH AG Maintenance of Genome Stability » Tour of RPTC “Genome, Transcriptome and Proteome » 10:00 – 11:00 a.m. Transfer to Penzberg Dynamics in Aneuploid Cells” 11:15 – 12:45 a.m. Roche Diagnostics GmbH Dr. Roland Wedlich-Söldner Head of the Max Planck Research Group: Dr. Bernhard Skrobranek Cellular Dynamics and Cell Patterning Head of Occupational Safety, Environmental Protection, and » “Microscopy Approaches to Study Cellular Organization” Quality Management Welcome and introduction to Roche’s biotechnology site in Group 2: » Penzberg Dr. Marc Schmidt-Supprian Adrian von Sigriz Head of the Emmy Noether Research Group: Senior Vice President of Global R&D, Roche Applied Science Molecular Immunology and Signal Transduction » Roche Applied Science » “Modeling Oncogenic NF-kB Activation in Mice” Tuesday, December 6, 2011 Wednesday, December 7, 2011 Dr. Ralf Schumacher 8:00 a.m. Transfer to Tübingen Head of Biologics Research and pRED Center Manager 9:30 – 1:00 p.m. Hertie Institute for Clinical Brain Research – HIH Penzberg » Pharma Research and Early Development; Biologics Introduction to the Neurocampus in Tübingen Dr. Friedrich Feuerhake Dr. Annette Klepper Head of Experimental Pathology Head of Department, Structure and Development Planning Pharma Research and Early Development, pRED » Introduction to the University Hospital and the medical » Tissue Biomarkers and Pathology faculty Translational Research Sciences Prof. Dr. Holger Lerche Dr. Christian Meisel Director, Department of Neurology and Epileptology Oncology Site Leader and Head of Translational Executive Board of Directors Medicine Penzberg » Introduction to the Hertie Institute for Clinical Brain Research Pharma Research and Early Development, pRED Prof. Dr. Mathias Jucker » Oncology Research and Early Development Director, Department of Cellular Neurology Dr. Jochen Hurlebaus Executive Board of Directors Introduction to the German Center for Neurodegenerative Head of Central R&D Services – Innovation & Program

Program Program » IP Management Diseases 8 » Roche Professional Diagnostics Anita Meier-Kanke 9 12:45 – 2:00 p.m. Lunch and scientiﬁ c exchange in foyer 050 with postdocs from Head of ofﬁ ce for EU and international funding schemes, the areas previously introduced technology transfer, invention disclosures, and summer courses Funding possibilities in Germany and the EU 2:00 – 2:15 p.m. Walk to Biologics II » Dr. Simone Di Giovanni 2:15 – 3:45 p.m. Parallel groups: Group Leader, Independent Research Dr. Klaus Reichert » Being an independent research group leader at the Director Downstream Processing Hertie Institute for Clinical Brain Research Group 1: Pegasys fermentation and downstream » Dr. Della David Dr. Marc Preuß Group Leader, Junior Research Plant Manager API » Being a junior research group leader at the German Center » Group 2: Pegasys fermentation and downstream for Neurodegenerative Diseases 3:45 p.m. Coffee break (in the foyer of building 232) Lena Burbulla and Jasmin Hefendehl Presentation of PhD thesis 4:15 p.m. Transfer to Stuttgart via Ulm for dinner » 1:00 – 2:00 p.m. Lunch at the Hertie Institute for Clinical Brain Research 7:15 – 8:30 p.m. Dinner at the restaurant Ratskeller Ulm

10:30 p.m. Check-in at the hotel

Accommodation Schlosshotel Monrepos, Stuttgart Wednesday, December 7, 2011 Thursday, December 8, 2011 2:00 – 2:30 p.m. Prof. Dr. Horst Herbert Checkout Dean of Studies 8:00 a.m. Transfer Werner Reichardt Centre for Integrative Neuroscience (CIN) University of Tübingen 9:00 – 11:30 a.m. Fraunhofer Institute for Interfacial Engineering and » Presentation of the Graduate Training Centre of Biotechnology – IGB Neuroscience Dr. Günter Tovar 2:30 – 3:30 p.m. Parallel guided lab visits: Deputy Director, Institute for Interfacial Engineering (IGVT) University of Stuttgart Prof. Dr. Arthur Melms Research at IGVT and IGB Director, Department of General Neurology » Executive Board of Directors Dr. Karin Lemuth » Group 1: General Neurology Head of Biological Interfacial Engineering, IGVT University of Stuttgart Prof. Dr. Hans-Peter Thier Research in biological interfacial engineering at IGVT Director, Department of Cognitive Neurology » Executive Board of Directors Dr. Monika Bach » Group 2: Cognitive Neurology Head of Chemical Interfacial Engineering, IGVT University of Stuttgart Program Program Program Prof. Dr. Thomas Gasser Research in Chemical Interfacial Engineering at the IGVT Director, Department of Neurodegenerative Diseases » 10 11 Executive Board of Directors Jennifer Bilbao » Group 3: Neurodegeneration Co-head of Environmental Interfacial Engineering, IGVT University of Stuttgart Prof. Dr. Mathias Jucker Research in environmental interfacial engineering at IGVT Director, Department of Cellular Neurology » Executive Board of Directors Dr. Jan Hansmann » Group 4: Cellular Neurology Head of Medical Interfacial Engineering, IGVT University of Stuttgart Prof. Dr. Holger Lerche Research in medical interfacial engineering at IGVT Director, Department of Neurology and Epileptology » Executive Board of Directors Dr. Jakob Barz » Group 5: Neurology and Epileptology Head of Physical Interfacial Engineering, IGVT University of Stuttgart 3:30 – 4:30 p.m. Informal get-together with coffee and tea » Research in physical interfacial engineering at IGVT 4:30 – 6:00 p.m. Closed session, DAAD (2nd ﬂ oor, room: 310) Guided lab tour 6:00 p.m. Transfer 11:30 – 1:30 p.m. Transfer to Heidelberg 6:30 – 8:30 p.m. Dinner at the restaurant Reefs in Tübingen 1:30 – 2:10 p.m. Welcome and lunch 8:30 – 9:45 p.m. Transfer to hotel Lena Raditsch, Head of Communications

Accommodation Schlosshotel Monrepos, Stuttgart Thursday, December 8, 2011 Friday, December 9, 2011 2:15 – 3:00 p.m. European Molecular Biology Laboratory – EMBL Dr. Stefanie Seltmann Head of Press and Public Relations Dr. Silke Schumacher “The German Cancer Research Center – An Overview” Director, International Relations » » Introduction to EMBL Prof. Dr. Michael Boutros Head of Division, Signaling and Functional Genomics 3:00 – 4:00 p.m. Three parallel sessions: » The International Helmholtz Graduate School Dr. Silke Schumacher for Cancer Research Director, International Relations 10:30 a.m. Coffee Break » Group 1: EMBL graduate program and international partnerships 11:00 – 12:00 p.m. Individual discussions with scientists Dr. Francesca Peri Prof. Dr. Dr. Wolfhard Semmler Group Leader Head of Division Medical Physics in Radiology » Group 2: Microglia, the guardians of the brain » Group 1: “Better Diagnosis for Better Treatment” Dr. Jan Korbel Prof. Dr. Andreas Trumpp Group Leader Head of Division, Stem Cells and Cancer Group 3: Exploring the impact of genomic DNA rearrange- Group 2: “Cancer Stem Cells in Cancer Development and Program

Program Program » » ments in the germline and cancer through deep sequencing Metastasis”

12 4:00 – 4:30 p.m. Coffee break Prof. Dr. Ana Martin-Villalba 13 Head of Division, Neurobiology of Brain Tumors 4:30 – 5:30 p.m. Dr. Gábor Lamm Group 3: “New Treatments for Glioblastoma” Managing Director, EMBLEM » » “Innovation Works: Technology Transfer@EMBL” 12:00 – 12:45 p.m. Lunch at DKFZ 5:30 – 6:00 Transfer to the hotel and check-in 12:45 p.m. Transfer to NCT

7:15 p.m. Walk to the restaurant 1:00 – 2:30 p.m. Visit to the National Center for Tumor Diseases – NCT

7:30 – 9:00 p.m. Dinner at the Wirtshaus Zum Seppl Prof. Dr. Holger Sültmann Head of Independent Research Group: 9:00 p.m. Walk to the hotel Cancer Genome Research Accommodation Hotel Zum Ritter St. Georg, Heidelberg » “Research and Clinic Under One Roof” 2:30 p.m. Transfer back to DKFZ Friday, December 9, 2011 2:40 – 3:30 p.m. Poster presentation 08:15 a.m. Transfer » Graduate students from DKFZ 9:00 – 10:30 a.m. German Cancer Research Center – DKFZ Discussions with students

Prof. Otmar D. Wiestler 3:30 p.m. Coffee Chairman and Scientiﬁ c Member of the Management Board 3:45 – 4:15 p.m. Transfer to the hotel » Welcome to the German Cancer Research Center Friday, December 9, 2011 4:30 – 6:00 p.m. City tour of historic Heidelberg Dr. Carmen ABATE Andreas Reimelt ITALY Tour guide Meeting point: lobby of the Hotel Zum Ritter St. Georg Dipartimento Farmaco-Chimico 7:30 – 9:30 p.m. Farewell dinner at the restaurant Zum Ritter (at the hotel) Università degli Studi di Bari Accommodation Hotel Zum Ritter St. Georg, Heidelberg End of ofﬁ cial program

Saturday, 10 December 2011 Departure according to individual arrangements Dr. Abate holds a PhD in medicinal chemistry from the University of Bari and completed postdoctoral work in the same ﬁ eld & Escort Science Tour 2011 Dr. Christian SCHÄFER as a Fulbright research scholar at Virginia Commonwealth University (USA). She is now Participants Program Program Head of Section: Internationalisation of Research working as a research associate in the University German Academic Exchange Service (DAAD) of Bari’s Faculty of Medicinal Chemistry, 14 15 [email protected] where her interests include the development of sigma receptor ligands for the treatment Anne KNAB and diagnosis of CNS diseases and tumors.

Project Ofﬁ cer, Section: Marketing for Research f.nbjm; [email protected] German Academic Exchange Service (DAAD) [email protected] Friedrich MALTZAHN » I would like to meet experts in On behalf of MICHEL International Relations & Services the ﬁ elds of cancer therapy and [email protected] diagnosis, as well as in neurodegenerative diseases. I expect a wealth of information related to research, Rebecka MICHEL collaborations, and PhD student exchange programs. MICHEL International Relations & Services [email protected] (from December 3 to 4) Prof. Yi-Ming CHEN Dr. Chi-Shiun CHIANG TAIWAN TAIWAN

Director, AIDS Prevention and Research Center Professor, Department of Biomedical Engineering Professor, Institute of Microbiology and Immunology and Environmental Sciences National Yang-Ming University National Tsing Hua University

In addition to receiving degrees in medicine Dr. Chiang earned his PhD in biomedical and immunology from National Yang-Ming physics from the University of California at Los University, Prof. Chen completed an ScD in Angeles (USA) and now serves as a profes- cancer biology at the Harvard School of sor in the Department of Biomedical Engineer- Public Health (USA) and postdoctoral re- ing and Environmental Sciences at National Participants Participants search at the National Cancer Institute (USA). Tsing Hua University. He has published more He is now a faculty member at the Institute of than 50 scientifi c papers and performed 16 17 Microbiology and Immunology at National research as part of a scholarship from the Yang-Ming University. Prof. Chen has pub- Alexander von Humboldt Foundation in lished more than 120 papers on infectious 2000. In his work, Dr. Chiang’s primary diseases and liver and prostate cancer, and interests include multidisciplinary cooperative holds fi ve patents. He also received the Out- research on using macrophages in therapy standing Research Award from the National for cancer and neurodegenerative diseases. Science Council of Taiwan in 2009 and the National Innovation Award in 2011. Prof. f.nbjm; [email protected] Chen’s research interests include AIDS, anal- » I am interested in meeting ysis of glycine N-methyltransferase in cancer » I’m looking for cooperative and exchanging information with (liver, prostate) and neurodegenerative dis- research opportunities in cancer experts in the fi eld of cancer and eases, and cancer drug development. therapy and neurodegenerative neurodegenerative diseases. diseases between our department f.nbjm; [email protected] and German research institutions. I also want to learn more about the German higher education system. Dr. Marwan El-SABBAN Prof. Dr. Willy FLEGEL LEBANON USA

Professor of Cell Biology Chief, Laboratory Services Section Director of Biological Imaging Department of Transfusion Medicine Medical Faculty NIH Clinical Center, Maryland American University of Beirut

After completing his postgraduate studies in Since receiving his degree in medicine from clinical biochemistry at Oxford University, the University of Frankfurt/Main (Germany), Dr. El-Sabban received postdoctoral train- Prof. Flegel has worked as a private lecturer ing in the Department of Pharmacology at (Privatdozent) and associate professor (apl. Cornell University (USA). He then worked as Prof.) at the University of Ulm (Germany). Participants Participants a research associate at Cornell’s Department He has produced more than 100 peer-revie- of Pathology, as well as in the Department of wed publications, including a medical-legal 18 19 Neuroscience at Albert Einstein College of textbook on transfusion medicine patents in Medicine (USA). From there, Dr. El-Sabban blood group genotyping. In addition to this became an assistant professor of medicine at fi eld, Prof. Flegel’s research interests include SUNY Stony Brook (USA) and the director of relationships among genotypes, phenotypes, cell biology laboratories at Winthrop-University and the function of blood group proteins; » I believe that by acquiring fi rst- Hospital (USA). He has published over 80 stem-cell surface antigens during in vivo and hand information through dialogue manuscripts with both intra- and extramural ex vivo expansion; and immunogenetics in and discussions while visiting the funding, and his research interests range from hematopoietic stem-cell transplantation. various institutions, we are likely to the role of cell-cell and cell-matrix interaction establish a platform for fostering in cellular function to the interaction between f.nbjm; bill.fl [email protected] » Having established my and enhancing scientifi c exchange host tissues and cancer cells. laboratory at the NIH Clinical and carve new avenues for scienti- Center in 2009, I am now looking fi c collaboration. f.nbjm; [email protected] for exchanges of postdoctoral researchers (MD, PhD) from Ger- man academia and collaborations in molecular diagnostics/personalized medicine in my fi elds of research interest. Dr. Marc-André FORTIN Dr. J. A.GONZÁLEZ- HERNÁNDEZ CANADA CUBA

Assistant Professor of Materials Science and Chief, Department of Neuropsychology Biomedical Engineering Hermanos Ameijeiras Hospital Université Laval / Centre Hospitalier de Québec (CHUQ) University of Medical Sciences of Havana

Dr. Fortin earned his bachelor’s degree Dr. González-Hernández holds a master’s de- in materials science and engineering from gree and PhD from the University of Havana École Polytechnique de Montréal and his (Cuba) and is a fellow of both the German PhD in medical and applied physics from Academic Exchange Service (DAAD) and Institut National de la Recherche Scientiﬁ que the Alexander von Humboldt Foundation. He Participants Participants (INRS, Montréal). He then went on to com- is currently a senior professor in the Univer- plete postdoctoral research in nanotechnol- sity of Havana’s medical faculty. In addition 20 21 ogy (MRI) and radiotracers (PET) at Uppsala to publishing more than 30 scientiﬁ c papers, University and Linköping University (Sweden). Dr. González-Hernández holds one patent Since 2007, Dr. Fortin has been an assistant and has received numerous national and professor at Université Laval and CR-CHUQ. international awards. Some of his research He has also published 15 papers on materials interests include brain functions under different science and nanotechnology – as well as mental states, the development of neurophysical their applications in medicine – and holds a biomarkers, and functional neuroimages. » I hope to meet experts in high- patent concerning the synthesis of magnetic resolution microscopic techniques and radioactive particles. Among Dr. Fortin’s f.nbjm; [email protected] for characterizing the fate and research interests are the development and » I’d like to meet experts in microenvironments of nanoparticles characterization of probes for molecular and neurophysiological biomarkers and and tracers ingested by cells, bio- cellular imaging. mental states. I expect a wealth of logists interested in cell labeling for information – not only in terms of MRI tracking, and experts in PET/ f.nbjm; [email protected] research, but sharing and MRI. I’m also planning to study in networking, as well. Germany (2013-2014), hence my interest in developing a network of contacts (potential collaborations, joint grant applications, student mobility, and PhD co-supervisions). Dr. Dennis K. HORE Dr. Baiba JANSONE CANADA LATVIA

Assistant Professor, Department of Chemistry Assistant Professor, Department of Pharmacology University of Victoria University of Latvia

After receiving his BSc in chemistry at Mc- Having received her PhD in medicine (phar- Master University (Canada) in 1996, macology) from the University of Latvia, Dr. Hore earned a PhD in physical chemistry Dr. Jansone is now a senior researcher in the from Queen’s University (Canada) in 2002 Faculty of Medicine at the University of Latvia and conducted research as a postdoctoral in its Department of Pharmacology. She has Participants Participants fellow in Geri Richmond’s group at the published more than 50 scientifi c conference University of Oregon (USA) from 2003 to abstracts and papers, and is also heading 22 23 2006. His current research interests involve an ESF grant project investigating the role of the development of combined experimental neuroimmune regulation in the treatment of (including nonlinear vibrational spectroscopy) neurodegenerative disorders by the novel and modeling (including molecular dynamics type of privileged structures. In addition, simulation) techniques for elucidating the Dr. Jansone received the L’Oréal-UNESCO structure of biomolecules attached to solid Fellowship “For Women in Science” in 2007 surfaces, as well as understanding the role and was appointed president of the Latvian of solvents in promoting surface-induced Society of Pharmacology in 2010. Her main » On the tour, I hope to establish structural changes. research interests include neuropharmacol- academic and industrial research ogy, behavioral in vivo studies, neurodegen- » My academic and scientifi c collaborations in the areas of bio- f.nbjm; [email protected] erative diseases, and neuroinfl ammation. interest in the Science Tour is materials science, protein structures based on the unique opportunity on surfaces, and biomolecular f.nbjm; [email protected] to meet outstanding scientists and spectroscopy; learn about inter- academic staff in Germany and national educational, academic, develop cooperative efforts in industrial, and other institutional different fi elds. research programs related to molecular health sciences; and set up joint training programs for graduate students and postdoctoral fellows. Dr. Michael KOLIOS Prof. Dr. Helen LIAPIS CANADA USA

Associate Professor, Department of Physics, Professor of Pathology, Immunology University of Toronto and Internal Medicine (Nephrology) Graduate Program Director, Biomedical Physics Program, Washington University School of Medicine Ryerson University Canada Research Chair in Biomedical Applications of Ultrasound

In addition to winning the Premier’s Research Prof. Liapis’s academic accomplishments Excellence Award and a Canada Research span from a medical diploma from the Uni- Chair, Dr. Kolios has published 43 articles versity of Athens and a research internship in peer-reviewed journals and 133 confer- at University College London to a pathology Participants Participants ence papers. He is also a member of many residency and renal fellowship at Wash- committees – including the IEEE International ington University in St. Louis (USA). She is 24 25 Ultrasonics Symposium and the American now a professor at the same institution, as Institute of Ultrasound in Medicine (AIUM) well as the director of renal pathology and – and serves on the editorial boards of electron microscopy laboratories at the O’Brien Ultrasound in Medicine and Biology and Ultra- Kidney Center. In addition to working as a sound Imaging. Dr. Kolios has obtained three book editor and holding one patent, Prof. patents with two more pending. In addition, Liapis has published over 100 scientiﬁ c he is currently supervising 11 students (and papers and 20 book chapters. She also has done so for 17 students in the past). received the Jacob Churg Award for her Dr. Kolios’s research interests include biomed- outstanding contributions to renal pathology. ical applications of ultrasound and optics, In her research, Prof. Liapis maintains a » I want to explore the potential ultrasound/optical imaging, and high-frequen- particular interest in developmental/cystic » I’d like to meet experts in of developing student exchange cy ultrasound imaging and spectroscopy. kidney disease and obstructions, diabetes, the ﬁ eld of kidney research and programs and joint programs (such and transplant pathology. familiarize myself with Germany’s ascotutelle programs), as well as f.nbjm; [email protected] biomedical research institutions establish new research collabora- f.nbjm; [email protected] and industry. tions with scientists at the institutes we visit. Dr. Anne LUEBKE Dr. Ambika MATHUR USA USA

Associate Professor of Biomedical Engineering, Associate Dean, Graduate School Director, MD/PhD Neurobiology and Anatomy Dual-Degree Program Professor University of Rochester Medical Center Department of Pediatrics Wayne State University

In addition to holding a PhD in biomedical Dr. Mathur earned her PhD from the Uni- engineering from Johns Hopkins University, versity of Iowa (USA) and has held faculty Dr. Luebke has received over 20 years of appointments at the University of Minnesota continuous NIH funding for inner-ear research and West Virginia University. In addition to and is a lifetime member of Phi Kappa Phi. promoting graduate education, she is inter- Participants Participants During her undergraduate studies, she also ested in researching the regulation of the completed a summer internship as a chemical immune responses of T lymphocytes and 26 27 engineer at Linde AG in Munich (Germany). cytokines. Dr. Luebke’s research reﬂ ects her interest in the molecular biology of cochlear efferent f.nbjm; [email protected] feedback systems and genetically modiﬁ ed mouse models for human testing of efferent feedback strength in children with autism.

f.nbjm; [email protected] » I look forward to arranging » Wayne State University would summer experiences with German like to develop partnerships with institutions and companies for engi- German institutions to promote neering and neuroscience students master’s, doctoral, and postdoc- from the University of Rochester, toral educational programs and and organizing research exchan- exchanges. ges for graduate and undergraduate students. Prof. Dr. Hala MOHTASEB Dr. Donna M. MURASKO LEBANON USA

Professor of Biology Dean and Professor of Biology, Department of Biology College of Arts and Sciences American University of Beirut Professor of Microbiology and Immunology, College of Medicine Drexel University

After obtaining her PhD in biology from Kan- Dr. Murasko received her PhD in microbio- sas State University (USA), Prof. Mohtaseb logy from Hershey Medical Center at Penn worked as a research associate at Case State University (USA), after which she joined Western Reserve University of Cleveland, the faculty of the Medical College of Penn- Ohio. She has been a professor of biology at sylvania as an assistant professor. She has Participants Participants the American University of Beirut since 1994, since been promoted to professor and chair published more than 75 scientifi c papers, and of the Department of Microbiology and Im- 28 29 received three international research awards. munology. Dr. Murasko has also published Cancer prevention and therapy – particularly more than 100 peer-reviewed scientifi c pa- in identifying cellular and molecular action pers – as well as numerous book chapters mechanisms of plant-derived anticancer drugs and review articles – and been the recipient – represent some of her primary research of 33 years of continuous NIH funding. Her interests, along with identifying novel hypoxic research interests include changes in immune cytotoxins and radiation modifi er drugs. response that occur with increasing age and » Scientifi c trainees need to the impact of these changes on viral infec- learn the importance of internatio- f.nbjm; [email protected] tions. nal collaboration and the societal » I’d like to meet potential needs of both the United States cooperative partners with expertise f.nbjm; [email protected] and other nations. This tour will in the fi eld of cancer chemopreven- help me understand the breadth tion and chemotherapy. of research at the various institutions and the interests of specifi c investigators in forging exchanges with Drexel University. I will then be able to encourage my faculty to pursue training opportunities for our students and collaborative research opportunities. Dr. Ceferino OBCEMEA Dr. Rima ROZEN USA CANADA

Chief Physicist and Associate Attending Associate Vice Principal, Research Departments of Radiation Oncology and Medical Physics and International Relations Memorial Sloan-Kettering Cancer Center James McGill Professor McGill University

Dr. Obcemea followed up his PhD in physics After earning her PhD in human genetics from the University of Uppsala (Sweden) with from McGill University, Dr. Rozen received fellowships at the NCI Radiological Physics postdoctoral training in biochemistry at the Center and Harvard Medical School (USA). same institution, as well as in human genet- He also won the Faculty Research Award on ics at Yale University (USA). A James McGill Participants Participants New Technology from Georgetown University Professor, her achievements include the publi- Medical Center. Dr. Obcemea has since cation of over 200 articles and several awards, 30 31 published research in the ﬁ elds of physics, along with membership in the Royal Society of medical physics, and interdisciplinary topics Canada and 10 patents. Dr. Rozen also such as chaos theory analysis of tumor served as director of Montreal Children’s growth dynamics. His other research interests Hospital at McGill University from 1999 to include plasma accelerators for ion-beam 2007. She has since been associate vice cancer therapy, mathematical modeling of principal of the university’s research and in- tumor growth dynamics, and microdosimetric ternational relations. In her own research, Dr. aspects of radiation oncology. Rozen’s interests range from genetic-nutritional interactions to vascular disease and cancer. » I am interested in meeting f.nbjm; [email protected] » McGill is a research-intensive experts in proton and ion therapy f.nbjm; [email protected] university with particular strengths in in Munich and Heidelberg, as well the health sciences, including neu- as in establishing possible joint roscience, genomics/epigenomics, research projects with them. infectious disease, developmental biology, and computational biology. We welcome partnerships with other strong international institutions in these and other relevant areas. Dr. Dar-Bin SHIEH Prof. Dr. Bing-Wen SOONG TAIWAN TAIWAN

Professor and Chairman, Institute of Oral Medicine Deputy Chair, Department of Neurology Attending Physician and Session Chair of Stomatology National Yang-Ming University School of Medicine National Cheng Kung University

Dr. Shieh has received doctorates in dental Along with earning his medical degree from surgery from National Yang Ming University the National Defense University College (Taiwan) and in medical science from Harvard of Medicine (Taiwan) and his PhD from University (USA). He is now a distinguished National Yang-Ming University, Prof. Soong professor at the NCKU Center for Micro/ completed a neurology training residency at Participants Participants Nano Science and Technology. In 2011, the Washington University School of Medicine Dr. Shieh won the Outstanding Research from 1982 to 1983. He then worked at the Uni- 32 33 Award from the Taiwan National Science versity of Texas Health Science Center (USA, Council. He is the founding chief editor of 1983-1985) and participated in a fellowship NCKU Research Express (http://research. and in research training at NINCDS (USA, ncku.edu.tw/re/), has published over 80 1985-1987). Prof. Soong currently holds scientifi c papers, and is named as an inventor a professorship in the Faculty of Medicine on more than 40 patents. Dr. Shieh’s research at National Yang-Ming University. He has focuses mainly on translational nanomedicine also published 100 scientifi c papers and and structural biology – especially on oncology received numerous accolades. In terms of and infectious diseases – as well as on research, Prof. Soong’s interests include » The Science Tour is an excel- the development of advanced medical neurodegenerative disorders – such as he- » I would like to meet experts in lent portal for meeting experts in devices and biomaterials for improved clinical reditary and sporadic ataxias and hereditary the fi eld of neurogenetic disorders Germany and seeking potential sy- disease management. spastic paraplegia – and personalized medi- and personalized medicine; I also nergistic collaborations. It is also a cine. hope to obtain plenty of informati- good chance to explore the culture f.nbjm; [email protected] on on research and collaboration. and system of the science commu- f.nbjm; [email protected] nity in Germany. I look forward to acquiring a wealth of information in my topics of interest and connecting with a global network of contacts through this opportunity. Prof. Dr. Jack TUSZYNSKI Dr. Ching TZAO CANADA TAIWAN

Allard Research Chair, Oncology Director, Center for Experimental Surgery Professor of Physics Associate Professor and Attending Surgeon, University of Alberta Tri-Service General Hospital National Defense Medical Center

Prof. Tuszynski holds two degrees in phys- Dr. Tzao completed his PhD studies in ics – an MSc from the University of Poznań pathology at the State University of New York (Poland) and a PhD from the University of in Buffalo and fellowship training at Duke Calgary (Canada) – and has been an as- University Medical Center’s Department of sistant professor at the Memorial University Cardiothoracic Surgery (USA). He has pub- Participants Participants of Newfoundland (Canada). He has also lished more than 65 scientifi c papers and worked as a research manager at Starlab in received corresponding awards for excel- 34 35 Brussels (Belgium) and held visiting professor- lence from the Taiwan chapter of the Interna- ships in France, Belgium, Denmark, Germany, tional College of Surgeons in 2005, 2007, and China. In addition to publishing more and 2009. One of Dr. Tzao’s abstracts also than 300 scientifi c papers and 10 books, won an award from the International Society Prof. Tuszynski is named as an inventor on for Diseases of the Esophagus (Japan) in 12 patents. His research interests range from 2010. His research interests include cancer computer-assisted drug discovery – especially epigenetics (DNA methylation and histone for cancer chemotherapy – to physiologically modifi cation), cancer stem cells, tumor based pharmacokinetic modeling and the microenvironments, cancer infl ammation, and » I’d like to maintain and expand biological systems of cancer. therapeutic targeting. » The institutions and companies my research links to German listed in the visiting program are science centers, especially in health f.nbjm; [email protected] f.nbjm; [email protected] outstanding picks. The research research. I was a Humboldt Fellow areas highlighted in this program and a visiting scientist in the Ger- are the most relevant and attractive man Academic Exchange Service ones to many cancer research (DAAD), and have collaborated institutions, including ours. Thanks with several groups in Germany in to this tour, we will hopefully have the past. the chance to establish constructive collaborative arrangements at the personal and institutional level. Prof. Dr. Ulrich POHL Vice President of International Affairs Ludwig Maximilians University of Munich (LMU)

Ludwig Maximilians University Prof. Ulrich Pohl has held the chair of vegetative physiology at LMU Munich’s Institute of Physiology since 1998. In 2006, he was also of Munich – LMU appointed head of the Institute of Surgical Research at the Medical Center of the University of Munich and director of the Walter Bren- The Ludwig Maximilians University of Munich (LMU) is one of Europe’s leading univer- del Center, a joint institution of LMU Munich and its Medical Center. sities with over 500 years of tradition. LMU Munich is divided into 18 comprehensive Pohl’s contributions to cardiovascular research have earned him the faculties which offer a diverse array of courses in some 150 subjects. It also has many Albert Fraenkel Prize, as well as the prestigious Malpighi Award. He interdisciplinary centers and one of Germany’s ﬁ nest library systems. LMU Munich was is past president of the Federation of European Physiological Societies quite successful in Germany’s nationwide initiative to promote elite university research, and the European Society of Microcirculation. Prof. Dr. Pohl took up receiving the highest level of appropriations, and has an outstanding research record his position as LMU’s Vice President of International Affairs in 2010. recognized by many university rankings. LMU is also one of largest universities in Germa- Institutions Institutions ny with nearly 50,000 students – almost 15% of whom come from abroad – and more than 700 professors. 36 37 Prof. Dr. Patrick CRAMER Head of Gene Center Ludwig Maximilians University of Munich (LMU)

Prof. Patrick Cramer has been chair of biochemistry and director of the Gene Center at the Ludwig Maximilians University of Munich since 2004. As a structural biologist, he has contributed to our understanding of the structure and function of RNAP II and its associated factors. In recent years, his laboratory has also developed functional genomics techniques to study how the transcription cycle is coordinated and how gene regulation occurs on a systemic level. Prof. Dr. Cramer is currently researching molecular systems biology. He is a member of the German Academy of Sciences Leopoldina and the Max Planck Society, and has received the Gottfried Wilhelm Leibniz Award and an ERC Advanced Investigator Grant. Prof. Dr. Georg MARCKMANN, MPH Director Institute of Ethics, History and Theory of Medicine Ludwig Maximilians University of Munich (LMU) BioM Biotech Cluster Prof. Georg Marckmann studied medicine and philosophy at the Uni- Development GmbH versity of Tübingen (Germany). He was a scholar at the postgraduate college “Ethics in the Sciences and Humanities” in Tübingen from 1992 BioM coordinates the Munich Biotech Cluster and the Bavarian biotechnology network. to 1995 and received his doctoral degree in medicine in 1997. From BioM is the ﬁ rst contact point for the local biotechnology sector and aims to develop the 1998 to 2010, he was an assistant professor at the Institute of Ethics region and strengthen its position as one of the leading biotech centers in Europe. BioM and History of Medicine at the University of Tübingen, also working offers a wide range of support services to regional biotech companies and incoming as vice director from 2003. In 2000, he received a master’s degree biotech players. Its website (www.bio-m.org) offers a company database, news up- in public health from Harvard University. In 2010, he became a full dates, and much more. In 2010, Munich was awarded „Leading-Edge Cluster“ status in professor and director of the Institute of Ethics, History and Theory of a cross-industry competition of the Federal Ministry of Research and Education (BMBF). Medicine at the Ludwig Maximilians University of Munich. Institutions Institutions This initiated the BioM-coordinated program “m4 - Personalized Medicine and Targeted Therapies” (www.m4.de). 38 39 Prof. Dr. Horst DOMDEY Managing Director BioM Biotech Cluster Development GmbH

Prof. Horst Domdey held biochemistry research positions in Europe and the United States before becoming a professor at the University of Munich in 1994. He co-founded MediGene, one of the ﬁ rst German biotech companies, and successfully led the Munich Biotech Initiative into the German BioRegio Competition in 1996. He then became Managing Director of BioM, the Munich Biotech Cluster management organization. Prof. Domdey holds leading positions in the Bavarian Genome Network and the Bavarian Center for Molecular Biosys- tems, and co-founded BIO Deutschland and the Council of European BioRegions (CEBR). Under his leadership, Munich was a winner in Germany’s “Leading-Edge Cluster” competition in 2010. Dr. Ralf TATZEL Assistant to the Board of Managing Directors Max Planck Institute of Biochemistry (MPIB)

Dr. Ralf Tatzel received his PhD from the Technische Universität Mün- chen (Germany) in 1992. From 1992 to 1997, he was the head of Max Planck Institute the “Molecular Biology” research group at the Bavarian State Ministry of Agriculture’s Regional Offi ce of Nutrition in Munich, Germany. In of Biochemistry – MPIB 1998, he made the switch to pure science management and has since been the assistant to the Board of Managing Directors of the Max Proteins are the molecular building blocks and engines of the cell, and are involved Planck Institute of Biochemistry near Munich, Germany. In this function, in almost all processes of life. The scientists at the Max Planck Institute of Biochemistry he provides extensive administrative support and heads the institute’s (MPIB) investigate the structure of proteins and how they function – from individual mole- Scientifi c Service Facilities. cules up to whole organisms. With about 850 employees from 45 nations, the MPIB is one of the largest institutes within the Max Planck Society. In currently eight departments Institutions Institutions and around 25 research groups, scientists contribute to the latest fi ndings in the areas of biochemistry, cell biology, structural biology, biophysics, and molecular science. 40 41 Dr. Andreas BRACHER Project Group Leader Research Department “Cellular Biochemistry“ Max Planck Institute of Biochemistry (MPIB)

Dr. Andreas Bracher, born in 1967, studied chemistry at the Tech- nische Universität München (Germany). He then completed his doctoral studies at the university’s Institute of Organic Chemistry and Bio- chemistry and was awarded his PhD in 1998. From 1999 to 2002, he was a postdoctoral fellow under Winfried Weissenhorn at EMBL Grenoble (France). Since then, he has been a project group leader in the Department of Cellular Biochemistry at the Max Planck Institute of Biochemistry near Munich, Germany. In 2009, Andreas Bracher habilitated at TUM. Dr. Mark Steffen HIPP Dr. Roland WEDLICH-SÖLDNER Project Group Leader Head of the Max Planck Research Group Research Department “Cellular Biochemistry“ “Cellular Dynamics and Cell Patterning” Max Planck Institute of Biochemistry (MPIB) Max Planck Institute of Biochemistry (MPIB)

Dr. Mark Steffen Hipp, born in 1974, studied physiological chemistry Dr. Roland Wedlich-Söldner received his PhD from the Ludwig and biochemistry at the Eberhard Karls Universität Tübingen (Germa- Maximilians University of Munich (Germany) in 2001. From 2002 ny). He then earned his PhD in 2005 from the University of Konstanz. to 2005, he was a postdoctoral fellow under Rong Li at Harvard From 2005 to 2010, he was a postdoctoral fellow at Stanford Uni- Medical School (USA). Since then, he has been the head of the Max versity (USA). Since 2010, he has been a project group leader in Planck Research Group “Cellular Dynamics and Cell Patterning” at the the Department of Cellular Biochemistry at the Max Planck Institute Max Planck Institute of Biochemistry near Munich, Germany. of Biochemistry near Munich, Germany. Dr. Hipp’s research focuses Dr. Wedlich-Söldner is interested in the spatial and temporal organi- on the mechanisms of toxicity in aggregation prone proteins and on zation of cells. Speciﬁ cally, his lab studies the mechanisms that drive ways to prevent harmful interactions between protein aggregates and cell polarization, reorganization of the cortical actin cytoskeleton, and essential cellular components. lateral organization of the plasma membrane. Institutions Institutions

42 43 Dr. Zuzana STORCHOVA Dr. Marc SCHMIDT-SUPPRIAN Head of the Max Planck Research Group Head of the Emmy Noether Research Group “Maintenance of Genome Stability” “Molecular Immunology and Signal Transduction” Max Planck Institute of Biochemistry (MPIB) Max Planck Institute of Biochemistry (MPIB)

Dr. Zuzana Storchova received her PhD from the Charles University in Dr. Marc Schmidt-Supprian received his PhD from the University of Co- Prague (Czech Republic) in 1999. She then spent two years as a re- logne (Germany) in 2003. From 2003 to 2004, he was a postdoc- search associate at the University of Zurich (Switzerland). From 2001 toral fellow under Klaus Rajewsky at the CBR Institute for Biomedical to 2007, she was a research associate at Harvard Medical School’s Research at Harvard Medical School (USA), where he continued as Dana Farber Cancer Institute (USA). Since 2008, she has headed the a junior investigator and instructor in pathology until 2007. Since then, Max Planck Research Group “Maintenance of Genome Stability” at Dr. Schmidt-Supprian has been the head of the Independent Research the Max Planck Institute of Biochemistry near Munich, Germany. Dr. Group “Molecular Immunology and Signal Transduction” at the Max Storchova’s research focuses on the mechanisms of genomic instability Planck Institute of Biochemistry near Munich, Germany. His research

in eukaryotic polyploids, the ways in which the altered physiology of focuses on the role of the NF-kB signaling pathway and the ROQ do- polyploid cells contributes to tumor development, and comparisons of main proteins in immune cell development, inﬂ ammation, autoimmunity, polyploidy and aneuploidy. and lymphomagenesis. Dr. Andreas PICHLMAIR Head of the Max Planck Research Group “Innate Immunity” Max Planck Institute of Biochemistry (MPIB)

Dr. Andreas Pichlmair studied veterinary medicine in Vienna and completed his doctoral thesis at the University of Freiburg (Germany) Rinecker Proton Therapy Center – RPTC in 2004. He then earned his PhD at the London Research Institute (Cancer Research UK). From 2008 to 2011, he was a postdocto- The Rinecker Proton Therapy Center (RPTC) is the fi rst European proton radiation center ral fellow at the Center for Molecular Medicine in Vienna, Austria. to offer a complete hospital setting for the outpatient treatment of tumors. Established by Since 2011, he has headed the Max Planck Research Group “Innate the surgeon Dr. Hans Rinecker, the center’s long-term goal is to set up additional facilities Immunity” at the Max Planck Institute of Biochemistry near Munich, in other cities and countries. Germany. Dr. Pichlmair is interested in how viral structures interact with RPTC commenced operations in 2009 and is designed to treat up to 4,000 patients host factors and infl uence antiviral immunity. His lab is also investiga- annually. It is available to patients with statutory or private health insurance. ting changes at the transcriptome and proteome levels following viral The facility is CE-certifi ed and approved by the Bavarian Environmental Agency for he- Institutions Institutions infection. alth care and is authorized to irradiate all tumors previously treated with X-ray radiation in accordance with international proton-therapy regimens. 44 45 Prof. Dr. Manfred HERBST Medical Director Medical Executive Board, PROHEALTH AG Rinecker Proton Therapy Center (RPTC)

After receiving his degree in medicine in 1967 and his medical license the following year, Prof. Manfred Herbst continued his studies and graduated in the ﬁ elds of internal medicine, radiology, and radiation oncology and therapy. He then habilitated in 1983 and became an associate professor (C3) in 1986. In 1991, he became a C4-level professor, as well as the medical director and head of the Department of Radiation Oncology at the University Hospital Regensburg (Ger- many). Prof. Dr. Herbst has been the medical director of the Rinecker Proton Therapy Center (RPTC) since 2004. His research interests range from interstitial and external hyperthermia to investigating the absorpti- on of protons in different tissues. Dr. Bernhard SKROBRANEK Head of Occupational Safety, Environmental Protection, and Quality Management Roche Diagnostics GmbH

Roche Diagnostics GmbH Dr. Bernhard Skrobranek, born in 1959, studied chemistry and biochemistry at the Ludwig Maximilians University of Munich and earned Roche Diagnostics GmbH is part of the Switzerland-based Roche group, a world leader his PhD in 1988. He then joined Boehringer Mannheim in Penzberg in in-vitro diagnostics, cancer medicine, transplantation, and virology. Based in Penz- (Germany) as a biosafety ofﬁ cer in the same year. Dr. Skrobranek berg (Germany), Roche operates one of Europe’s largest research, development, and became head of occupational safety in 1993 and has been head of production facilities for biotechnology-based diagnostics and active pharmaceutical in- occupational safety, environmental protection, and quality manage- gredients. The diagnostics portfolio comprises test systems for the life science market, ment at the company (now Roche Diagnostics GmbH) since 1999. medical diagnosis, patient stratiﬁ cation, and therapy monitoring. Its pharmaceutical division specializes in therapeutic human proteins with a focus on monoclonal antibodies Institutions Institutions and biomarkers for oncology. Stem-cell research was also recently added to the site’s portfolio. 46 47 Adrian VON SIGRIZ Senior Vice President of Global R&D, Roche Applied Science

Mr. Adrian von Sigriz earned his degree in chemical engineering from SGS INSTITUT FRESENIUS (Germany) and started his career in 1983 at Boehringer Mannheim, where he was a technical evaluation manager for new diagnostic systems. Mr. von Sigriz managed various projects and developed several new diagnostics systems, including Elecsys in 1996. After working as head of instrumentation at Roche Applied Science, Mr. von Sigriz was appointed vice president of instrumentation for near-patient testing. Following a term as senior vice president and head of R&D for near-patient testing, he was appointed senior vice president of global R&D at Roche Applied Science. Dr. Ralf SCHUMACHER Dr. Christian MEISEL Head of Biologics Research and Oncology Site Leader and pRED Center Manager, Penzberg Head of Translational Medicine, Penzberg Roche Diagnostics GmbH Pharma Research & Early Development (pRED) Roche Diagnostics GmbH Dr. Ralf Schumacher obtained his degree (Diplom) in biology from RWTH Aachen University (Germany) and his PhD from the Max Following his parallel studies of medicine and computer science, Planck Institute of Biochemistry. After performing postdoctoral work at Dr. Christian Meisel earned his PhD in molecular clinical pharmaco- Roche in Basel (Switzerland), he joined Boehringer Mannheim (now logy and obtained board certifi cation in clinical pharmacology and Roche Penzberg) in 1996. He then worked as a project leader in internal medicine. He is now a member of the American Society of Cli- oncology, a program manager in biopharmaceuticals, and the head nical Oncology (ASCO) and the American Association of Cancer Re- of biopharmaceuticals program management before taking on his cur- search (AACR), as well as a past German delegate for the European rent position as head of biologics research and pRED center manager Association for Clinical Pharmacology and Therapeutics (EACPT). in Penzberg in 2010. That same year, he became a member of the Dr. Meisel has also served on the drug commission of the German board of directors of European Biopharmaceutical Enterprises. Medical Association and the ethics committee of the Berlin Chamber Institutions Institutions of Physicians. 48 Dr. Friedrich FEUERHAKE 49 Dr. Jochen HURLEBAUS Head of Experimental Pathology Translational Research Sciences (TRS) Head of Central R&D Services – Roche Pharma Research and Early Development (pRED) Innovation & IP Management Roche Diagnostics GmbH Dr. Feuerhake received his medical degree from Hannover Medical School (Germany). His medical training included internal medicine Dr. Jochen Hurlebaus received his MSc in mathematical ecology from (Teaching Hospital of Hannover Medical School), microscopic anato- the University of Tennessee (USA) in 1997. He completed his PhD in my (LMU), and pathology / neuropathology (University of Freiburg). theoretical biology and bioinformatics in 2000 and continued with His research interest is focused on interactions between the immune postdoctoral work at DSM Netherlands. In 2001, he joined Roche system and malignant diseases; in this fi eld he worked as a research Diagnostics R&D as a project manager and later became a system fellow from 2002 – 2005 with the group of Dr. Margaret Shipp, project leader for PCR-based mutation scanning. In April 2007, he Dana-Farber Cancer Institute, Boston, MA, on CNS lymphoma and accepted a position in innovation concept development. He became aberrant NF-kB signaling in diffuse, large B-cell lymphoma. Dr. Feuer- head of innovation management in the Department for Innovation & hake is a board-certifi ed neuropathologist since 2004 and practiced IP Management within Roche Professional Diagnostics in 2008, and as a consultant neuropathologist at the University Clinic of Freiburg, has headed Central R&D Services – Innovation & IP Management Germany, from 2005 – 2008. He joined Roche as Head of Experi- since early 2011. mental Pathology in 2008, and holds a position as associate lecturer in neuropathology at the University of Freiburg since 2007. Dr. Marc PREUSS Plant Manager API Roche Diagnostics GmbH

Dr. Marc Preuß, born in 1972, studied chemistry at the Technische Universität Darmstadt (Germany) and earned his degree (Diplom-Inge- nieur) in 1999. Dr. Preuß joined the laboratory of Prof. Dr. W. Neupert at the Ludwig Maximilians University of Munich and was awarded his PhD in 2004. For his postdoctoral work, he joined the department of Dr. T. Dick (redox regulation) at DKFZ in Heidelberg. Dr. Preuß joined Roche in Penzberg as a manager of downstream processing in 2007. He oversaw the production of the active pharmaceutical ingredient of NeoRecormon and PEGASYS and is now a plant manager responsible for the API production of MIRCERA. Institutions Institutions

50 51 Dr. Klaus REICHERT Director of Downstream Processing Roche Diagnostics GmbH

Dr. Klaus Reichert, born in 1955, studied chemistry (Diplom) at the University of Ulm (Germany) and was awarded his PhD in organic chemistry in 1986. Dr. Reichert then worked for four years in the chro- matography research department at E. Merck in Darmstadt. In 1990, he joined Boehringer Mannheim in Penzberg as a chemist in the diagnostic department. He has worked on several development and manufacturing projects in the pharmaceutical department since 1995. Dr. Reichert is now director of downstream processing and responsible for the process of manufacturing the active pharmaceutical ingredients PEG-IFN and MIRCERA, as well as the small-scale Labs DSP. Prof. Dr. Thomas GASSER Director of the Department of Neurodegenerative Diseases Executive Board of Directors Hertie Institute for Clinical Brain Hertie Institute for Clinical Brain Research (HIH) Research – HIH Prof. Thomas Gasser is a professor of neurology and director of the The Center of Neurology at the University of Tübingen was founded in 2001 by mer- Department of Neurodegenerative Diseases at the Hertie Institute for ging the Hertie Institute for Clinical Brain Research (HIH) and the University Clinic for Clinical Brain Research (Germany). After studying medicine at the Neurology in an effort to promote excellence in research and patient care. Presently, University of Freiburg (Germany) and Yale University Medical School the center consists of four clinical departments and one basic science department. In less (USA), he received his professional training as a medical specialist in than 10 years, the Hertie Institute has grown to encompass more than 200 researchers, psychiatry/neurology at the Max Planck Institute of Psychiatry (Ger- from PhD students to full professors. It is home to a total of 23 research groups, the ﬁ rst many) and in neurology at the Department of Neurology at the Ludwig of which just passed its ﬁ rst evaluation by the Hertie Institute’s board of trustees and has Maximilians University of Munich (Germany). Prof. Gasser’s main are- been promoted from “junior” to “independent” group status. as of research include the genetic and molecular basis of Parkinson’s disease, dystonia and other movement disorders, as well as their dia- Institutions Institutions gnosis and treatment.

52 53 Prof. Dr. Mathias JUCKER Director of the Department of Cellular Neurology Executive Board of Directors Helmholtz Association– German Hertie Institute for Clinical Brain Research (HIH)

Centre for Neurodegenerative Prof. Mathias Jucker is a professor of cellular neurology and director of the Hertie Institute for Clinical Brain Research at the University of Diseases – DZNE Tübingen (Germany). The German Centre for Neurodegenerative Diseases (DZNE) is a research institute Prof. Dr. Jucker studied neurobiology and received his PhD from the within the Helmholtz Association responsible for studying neurodegenerative diseases. Swiss Federal Institute of Technology (ETH) Zurich in 1988 before Its mission is to understand the causes and risk factors that lead to a predisposition for becoming a postdoctoral research scientist at the National Institute on neurodegeneration and develop new therapeutic and health care strategies. In order Aging (NIH, USA). He returned to Switzerland as an assistant profes- to promote high-quality research in the ﬁ eld of neurodegeneration, the DZNE closely sor at the University of Basel (Switzerland) and was appointed to his collaborates with its partner universities. current position in Tübingen in 2003. Prof. Dr. Jucker’s main areas of research involve the cellular and molecular mechanisms responsible for brain aging and Alzheimer’s disease. Dr. Günter TOVAR Deputy Director, Institute for Interfacial Engineering (IGVT) University of Stuttgart

Fraunhofer Institute for Interfacial Private lecturer (Privatdozent) Dr. Günter Tovar is deputy director of the Institute for Interfacial Engineering (IGVT) at the University of Stuttgart Engineering and Biotechnology – IGB (Germany) and lectures on process engineering, technical biology, medical technology, and chemistry. He is the principal investigator of The Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB) in Stuttgart research projects on nanotechnology and biomaterials at IGVT and (Germany) is engaged in a broad spectrum of R&D work in the ﬁ elds of interfacial engi- the Fraunhofer Institute for Interfacial Engineering and Biotechnology neering and materials science, molecular biotechnology, physical process technology, (IGB) in Stuttgart. After obtaining his PhD from the Johannes Guten- environmental biotechnology and bioprocess engineering, and cell and tissue enginee- berg University in Mainz, Dr. Tovar habilitated at the University of ring. Its close cooperation with the Institute for Interfacial Engineering (IGVT) at the Stuttgart (“Biomimetic Interfaces via Hierarchically Structured Systems University of Stuttgart facilitates continuity from basic research to application. Under the for Molecular Recognition”) and obtained his venia legendi in 2004. Institutions Institutions joint management of Professor Thomas Hirth, the two institutes address the development of processes for medicine, pharmacy, chemistry, the environment, and energy. 54 55 Dr. Karin LEMUTH Head of Biological Interfacial Engineering, Institute for Interfacial Engineering (IGVT) University of Stuttgart

Dr. Karin Lemuth, born in 1975, studied technically oriented biology at the University of Stuttgart (Germany) and received her PhD in 2006 in the subject of E. coli K12 bacterial stress responses. Dr. Lemuth then performed postdoctoral work on the modeling of bacterial cells at IBVT. In 2008, she joined the MBT department at the Fraunhofer IGB, where she worked on DNA microarrays and infection biology. Since 2010, she has led the research group “Infection Biology and Array Technologies” at IGB and headed the Biological Interfacial Enginee- ring department at IGVT. Her main research topics are human fungal pathogens, infection biology, diagnostic DNA microarrays, and E. coli K12 stress responses. Dr. Monika BACH Dr. Jan HANSMANN Head of Chemical Interfacial Engineering, Head of Medical Interfacial Engineering, Institute for Interfacial Engineering (IGVT) Institute for Interfacial Engineering (IGVT) University of Stuttgart University of Stuttgart

Dr. Monika Bach manages the Chemical Interfacial Engineering Dr. Jan Hansmann, born in 1979, studied technical cybernetics at the (CGVT) group at the University of Stuttgart’s Institute for Interfacial Engi- University of Stuttgart (Germany) and obtained his doctoral degree in neering (IGVT). Her main research projects involve bio- and nanobio- 2010. He has managed the Medical Interfacial Engineering group materials, core-shell nanoparticles and capsules, and nanostructured, of the Institute for Interfacial Engineering since 2009. His research fo- biofunctional surfaces. Dr. Bach studied chemistry at the Technische cuses on the development of bioreactor systems for tissue engineering Universität München (Germany) and conducted her dissertation re- purposes. In this ﬁ eld, mathematical modeling is applied to determine search with a primary focus on catalysis at the University of Stuttgart’s the culture parameters of an optimal tissue-speciﬁ c environment or in- Inorganic Institute. She was also a temporary research fellow at CNRS vestigate the tissue response to external stimuli. in Grenoble (France), Institutions Institutions

56 57 Jennifer BILBAO, MSc Dr. Jakob BARZ Co-Head of Environmental Interfacial Engineering, Head of Physical Interfacial Engineering, Institute for Interfacial Engineering (IGVT) Institute for Interfacial Engineering (IGVT) University of Stuttgart University of Stuttgart

Ms. Jennifer Bilbao, born in 1981 in Quito (Ecuador), studied env- After receiving his physics degree (Diplom) from the University of ironmental engineering at the Universidad San Francisco de Quito, Stuttgart (Germany) in 2003, Dr. Jakob Barz went on to work as Ecuador (2004). In 2001 and 2002, she was awarded the Breth- a scientist at the Fraunhofer Institute for Interfacial Engineering and ren Colleges Abroad scholarship to study in Juniata College (USA). Biotechnology (IGB) from 2007 to 2009 and earned his PhD at the In 2007, she received her master’s degree in environmental process university’s Institute for Plasma Research (IPF) in 2010. Since 2009, he engineering from the University of Stuttgart (Germany). Since 2008, has been a scientist at the Institute for Interfacial Engineering (IGVT) Ms. Bilbao has been working on her PhD in phosphorus recovery from and is now head of physical interfacial engineering. wastewater at the University of Hohenheim. Currently, she is leading the Nutrients Management group in the Physical Process Technology department at the Fraunhofer Institute IGB in Stuttgart, Germany. Dr. Silke SCHUMACHER Director, International Relations European Molecular Biology Laboratory (EMBL)

Dr. Silke Schumacher earned her ScD from the Université Paris XI in European Molecular 1997 and completed postdoctoral work at the National Institutes of Health (USA). She has also worked as a senior manager of phar- Biology Laboratory – EMBL maceutical business development at Merck KGaA and as a managing director at Anadys Pharmaceuticals Europe GmbH (Germany). After The European Molecular Biology Laboratory (EMBL) is Europe’s ﬂ agship laboratory working as a cooperation manager at EMBL in Germany from 2003 for the life sciences. Currently operating at ﬁ ve locations in Europe, EMBL is funded by to 2005, Dr. Schumacher was appointed director of international rela- public research funding from 20 member states and one associate member state. The tions and communications at the same institution in 2010. lab’s research is conducted by approximately 85 independent groups across the spectrum of molecular biology. The cornerstones of its mission are performing basic research in molecular biology; training scientists, students, and visitors at all levels; offering vital Institutions Institutions services to scientists; developing new instruments and methods in the life sciences; and actively engaging in technology transfer activities. 58 59 Dr. Francesca PERI Group Leader European Molecular Biology Laboratory (EMBL)

Dr. Francesca Peri earned her PhD from the University of Cologne (Germany) in 2002 and went on to conduct postdoctoral research at the Max Planck Institute for Developmental Biology (Germany). She has been a group leader at EMBL since 2008 and is an ERC investigator. Additional explanation (Dr. Francesca Peri): Dr. Jan KORBEL Dying cells in the developing brain must be cleared quickly and effi ciently by a resident lineage of “professional” phagocytes – the microglia. Despite the importance of microg- Group Leader lia in several neuronal pathologies, many fundamental questions concerning microglial European Molecular Biology Laboratory (EMBL) neuronal interactions remain unaddressed. We are studying the complex cell-cell interactions in vivo in the zebrafi sh (Danio re- rio), aiming to further exploit the massive imaging potential of the transparent zebrafi sh After obtaining his PhD from Humboldt-Universität zu Berlin and EMBL embryo to study microglial biology in vivo. By combining forward and reverse genetic (Germany) in 2005, Dr. Jan Korbel conducted postdoctoral research approaches with quantitative imaging technology, we are addressing the mechanis- at Yale University (USA). He has been working as a group leader at ms underlying the attraction of microglia towards apoptotic, sick, and injured neurons. EMBL since October 2008 in a joint appointment with the EMBL-EBI. Applying cutting-edge microscopy technology – such as SPIM/DSLM (selective plane illumination microscopy) – will enable us to image all interactions between neurons and microglia and derive from this time-lapse analysis real quantitative data in a spatiotem- poral manner.

Additional explanation (Dr. Jan Korbel): The Korbel group is applying experimental and computational approaches to study the Institutions Institutions extent, functional impact, and mutational and evolutionary origins of genetic variants, particularly genomic structural variants (SVs) – large-scale genomic deletions, insertions, 60 61 duplications, translocations, and inversions. SVs, also known as copy-number variants (CNVs), are among the last well-studied classes of genetic variation, despite their ha- Dr. Gábor M. LAMM ving a greater net effect on the human genome (in terms of affected base pairs) than single-nucleotide polymorphisms. The Korbel group uses next-generation sequencing Managing Director and computational algorithms to decipher the impact of SVs in normal variation and EMBL Enterprise Management Technology Transfer GmbH disease states, particularly cancer (e.g. prostate cancer, lymphoma, and medulloblasto- ma). The presentation will cover recent fi ndings on the mechanisms of formation and the impact of SVs on human disease, specifi cally pediatric brain tumors. Dr. Gábor M. Lamm graduated in biochemistry from Edinburgh Univer- sity (Scotland) and holds a PhD in molecular biology. After three years in research at the Boehringer Ingelheim Institute of Molecular Pathol- Additional explanation (Dr. Gábor M. Lamm): ogy (IMP, Austria), Dr. Lamm joined Wacker Chemie as a business EMBL Enterprise Management Technology Transfer GmbH (EMBLEM), established in team leader in the advanced ceramic components division. Since Oc- 1999, is an affi liate and the commercial arm of the European Molecular Biology Labora- tober 2000, he has been managing director of EMBL Enterprise Man- tory (EMBL). EMBLEM identifi es, protects and commercialises the intellectual property agement Technology Transfer GmbH (EMBLEM; www.embl-em.de). developed in the EMBL-world, from EMBL-alumni and from non-EMBL third parties includ- Dr. Lamm is an alumnus of the European Molecular Biology Laboratory ing the Life Science faculties of the University of Heidelberg . EMBLEM facilitates and ac- PhD program and the Boehringer Ingelheim Fonds, as well as a former celerates the transfer of innovative technology from basic research to industry by working vice president (2002-2006) of the Association of European Science closely with industrial partners spanning the biotech, pharmaceutical, IT and mechanical/ and Technology Transfer Professionals (ASTP). electrical engineering markets. For more information see www.embl-em.de.

Prof. Otmar D. WIESTLER Chairman and Scientifi c Member of the Management Board German Cancer Research Center (DKFZ) German Cancer Research After completing his medical training at the University of Freiburg’s Me- Center – DKFZ dical School (Germany), Prof. Otmar Wiestler received his MD in 1984 and trained as a postdoctoral fellow in the Department of Patho- The German Cancer Research Center (DKFZ) is the largest biomedical research institute logy at the University of California, San Diego (USA). He then worked in Germany. At DKFZ, more than 1,000 scientists work on investigating how cancer de- for fi ve years as a senior resident and assistant professor of neuropa- velops, identifying cancer risk factors, and fi nding new strategies to prevent the disease. thology at the University of Zurich (Switzerland) before moving to the In cooperation with Heidelberg University Hospital, DKFZ has established the National University of Bonn (Germany) in 1992. There he was appointed a Center for Tumor Diseases (NCT) in Heidelberg, where promising approaches from professor and head of the Department of Neuropathology and esta- cancer research are applied to clinical treatment. A member of the Helmholtz Associ- blished a major neuroscience research center. In January 2004, he ation of National Research Centers, the center receives 90 percent of its funding from joined DKFZ as chairman and scientifi c member of the management Institutions Institutions the Federal Ministry of Education and Research (BMBF) and the rest from the state of board. Baden-Württemberg. 62 63 Prof. Dr. Michael BOUTROS Head of Division for Signaling and Functional Genomics German Cancer Research Center (DKFZ)

After obtaining a degree (Diplom) in biochemistry from Witten/Her- decke University (Germany), Prof. Michael Boutros graduated sum- ma cum laude from the University of Heidelberg (Germany) in 1999 and earned an MPA from Harvard University’s Kennedy School of Government (USA) in 2001. He then completed his postdoctoral research under Norbert Perrimon at Harvard Medical School in 2003. From 2003 to 2008, Prof. Dr. Boutros worked as a group leader at DKFZ, where he has since been head of the Signaling and Functional Genomics division. His extensive research interests include genomic approaches to connect phenotypes and genotypes, synthetic genetic interactions, and signaling in development and disease. Prof. Dr. Dr. Wolfhard SEMMLER Prof. Dr. Ana MARTIN-VILLALBA Head of the Department of Medical Physics in Radiology Head of Division, Neurobiology of Brain Tumors German Cancer Research Center (DKFZ) German Cancer Research Center (DKFZ)

Prof. Wolfhard Semmler was awarded his physics degree from the Prof. Ana Martin-Villalba studied medicine at the University of Murcia Freie Universität Berlin (Germany) in 1976 and his medical degree (Spain) and the University of Leeds (UK). She received her PhD from from the University of Heidelberg in 1990. He started his career at the University of Heidelberg (Germany) and started her research ca- the University of Aarhus (Denmark), Rutgers University (USA), and Bell reer at DKFZ in 1999 as a group leader in the Immunogenetics di- Laboratories. In 1983, Prof. Dr. Semmler became an MR physicist at vision. Dr. Martin-Villalba is now division head of Neurobiology of the Freie Universität Berlin. From 1985 to 1991, he was head of the Brain Tumors. Her scientiﬁ c work has been published in dozens of MRS/MRI division at DKFZ and the scientiﬁ c and administrative di- prominent journals and she has received several awards, including the rector of the Freie Universität Berlin’s diagnostic research institute from Heinz Maier-Leibnitz-Preis and the Paul Ehrlich und Ludwig Darmstäd- 1992 to 1999. Since then, Prof. Dr. Semmler has been a full professor ter Young Investigator Award. She holds several patents, and her work at the University of Heidelberg and head of the Department of Medi- concentrates on the receptor for CD95 in nerve cells and brain and cal Physics in Radiology at DKFZ. pancreatic tumor cells. Institutions Institutions

64 65 Prof. Dr. Andreas TRUMPP PD Dr. Holger SÜLTMANN Head of Division of Stem Cells and Cancer Head of the Independent Research Group German Cancer Research Center (DKFZ) “Cancer Genome Research” German Cancer Research Center (DKFZ)

Prof. Andreas Trumpp is head of DKFZ’s Cancer and Stem Cells divi- Upon ﬁ nishing his studies in chemistry and biochemistry at the Uni- sion and managing director of the Heidelberg Institute for Stem Cell versity of Tübingen (Germany), Dr. Holger Sültmann completed his Technology and Experimental Medicine (HI-STEM). After completing diploma thesis at the Max Planck Institute for Biology under Prof. Dr. his PhD at EMBL in Heidelberg, he started his postdoctoral research Jan Klein. During his postdoctoral period, he worked as an assistant under Nobel Prize winner Prof. J. Michael Bishop in San Francisco professor and lecturer at the University of Tübingen. He habilitated in (USA). Later, Prof. Dr. Trumpp founded a research group at the Swiss genetics in the same university’s faculty of biology, which offered him Institute for Experimental Cancer Research (ISREC) in 2000 and beca- the possibility to work as group head at the German Cancer Research me a professor at École Polytechnique Fédérale de Lausanne (EPFL) Center (DKFZ) for a decade. He is currently employed as head of the in 2005. He and his team in Heidelberg have been investigating the independent research group “Cancer Genome Research” at DKFZ relationship between stem cells and cancer at the molecular, cellular, and the National Center for Tumor Diseases. and whole-body level since 2008. Hotels Escort: (December 4 - 6) +49 160 95 14 28 85 Friedrich Maltzahn Gästehaus am RPTC +49 163 26 09 26 0 Rebecka Michel Schäftlarnstrasse 135, 81371 München T: +49 89 66 06 70 +49 160 89 80 72 9 Dr. Christian Schäfer www.gh-rptc.de +49 160 90 53 37 78 Anne Knab (December 6 - 8) Emergency: Schlosshotel Monrepos Domäne Monrepos 2, 71634 Ludwigsburg 110 Police T: +49 7141 30 20 112 Fire brigade & ambulance www.schlosshotel-monrepos.de 11880 (additional fees apply) Telephone enquiry services (December 8 - 10) Hotel Zum Ritter St. Georg Taxicab services: Hauptstrasse 178, 69117 Heidelberg +49 711 55 10 00 0 Stuttgart T: +49 6221 13 50 +49 89 21 61 0 Munich www.ritter-heidelberg.de +49 6221 30 20 30 Heidelberg Hotels Important Numbers Hotels & Restaurants Restaurants +49 7071 68 88 89 Tuebingen Zum Flaucher 67 66 +49 8856 22 70 Penzberg December 4 Isarauen 8 T: +49 89 72 32 67 7 7:45 p.m. 81379 München www.zum-ﬂ aucher.de Airports: Hofer - Der Stadtwirt +49 1805 94 84 44 (additional fees apply) Stuttgart December 5 Burgstrasse 5 T: + 49 89 24 21 04 44 +49 1805 37 24 63 6 (additional fees apply) Frankfurt 7:30 p.m. 80331 München www.hofer-der-stadtwirt.de +49 89 97 50 0 Munich Ratskeller Ulm December 6 Marktplatz 1 T: +49 731 88 01 74 0 +49 1805 00 01 86 (additional fees apply) Berlin 7:15 p.m. 89073 Ulm www.ratskeller-ulm.de +49 211 42 16 66 6 Duesseldorf Restaurant Reefs Other important numbers: December 7 Europastrasse 40 T: +49 7071 97 98 00 7 6:30 p.m. 72072 Tübingen www.reefs.cc +49 1805 59 96 63 3 (additional fees apply) German Railway (Deutsche Bahn) +49 800 33 44 33 55 Western Union Bank

Wirtshaus „Zum Seppl“ +49 180 50 14 39 1 (additional fees apply) Lebara Prepaid Mobile December 8 Hauptstrasse 213 T: +49 6221 50 29 80 +49 89 41 42 43 44 Munich transport association 7:30 p.m. 69117 Heidelberg www.heidelberger-kulturbrauerei.de +49 711 19 44 9 Stuttgart transport association Zum Ritter St. Georg December 9 Hauptstrasse 178 T: +49 6221 13 50 +49 1805 8764636 (additional fees apply) Heidelberg transport association 7:30 p.m. 69117 Heidelberg www.ritter-heidelberg.de +49 6152 97 69 09 9 Lufthansa Airport Shuttle Biocenter at Ludwig Maximilians University of Munich – LMU Fraunhofer Institute for Interfacial Engineering and Biotechnology – IGB Biozentrum der Ludwig-Maximilians-Universtität München – LMU Fraunhofer-Institut für Grenzﬂ ächen- und Bioverfahrenstechnik – IGB December 5 Großhaderner Strasse 2 T: +49 89 21 80 0 December 8 Nobelstrasse 12 T: +49 711 970 4401 9:00 - 12:30 p.m. 82152 Planegg-Martinsried www.biologie.lmu.de 09:00 - 11:30 a.m. 70569 Stuttgart www.igb.fraunhofer.de

Institute for Interfacial Engineering – IGVT Gene Center Munich at Ludwig Maximilians University Munich – LMU Instituts für Grenzﬂ ächenverfahrenstechnik – IGVT Genzentrum der Ludwig-Maximilians-Universität München – LMU December 8 Nobelstrasse 12 T: +49 711 97 04 40 1 December 5 Feodor-Lynen-Strasse 25 T: +49 89 2180 76965 09:00 - 11:30 a.m. 70569 Stuttgart www.uni-stuttgart.de/igvt 09:00 - 12:30 p.m. 81377 Munich www.genzentrum.lmu.de BioM Biotech Cluster Development GmbH European Molecular Biology Laboratory – EMBL December 5 Am Klopferspitz 19a T: +49 89 899679 0 Europäisches Laboratorium für Molekularbiologie – EMBL 9:00 - 12:30 p.m. 82152 Martinsried www.bio-m.org December 8 Meyerhofstrasse 1 T: +49 6221 38 70 2:15 - 5:30 p.m. 69117 Heidelberg www.embl.de Max Planck Institute of Biochemistry – MPIB Max-Planck-Institut für Biochemie – MPIB German Cancer Research Center – DKFZ December 5 Am Klopferspitz 18 T:+49 89 85 78 0 Deutsches Krebsforschungszentrum – DKFZ 2:00 - 5:30 p.m. 82152 Martinsried www.biochem.mpg.de

December 9 Im Neuenheimer Feld 280 T: +49 6221 420 Institutions Adresses of Hotels Adresses of Institutions Rinecker Proton Therapy Center – RPTC 9:00 - 12:45 p.m. 69120 Heidelberg www.dkfz.de 68 69 December 6 Schäftlarnstrasse 133 T: +49 89 66 06 80 National Center for Tumor Diseases Heidelberg – NCT 08:30 - 09:45 a.m. 81371 Munich www.rptc.de Nationales Centrum für Tumorerkrankungen Heidelberg – NCT Roche Diagnostics GmbH December 9 Im Neuenheimer Feld 460 T: +49 6221 56 69 90 December 6 Nonnenwald 2 T: +49 08856 60 0 1:00 - 3:30 p.m., 69120 Heidelberg www.nct-heidelberg.de 11:00 - 04:15 p.m. 82377 Penzberg www.roche.de Site visit

Hertie Institute for Clinical Brain Research – HIH Hertie-Institut für klinische Hirnforschung – HIH December 7 Hoppe-Seyler-Strasse 3 T: +49 70 71 29 82 04 9 09:30 - 4:30 p.m. 72076 Tuebingen www.hih-tuebingen.de

German Centre for Neurodegenerative Diseases – DZNE Deutsches Zentrum für Neurodegenerative Erkrankungen – DZNE December 7 Otfried-Müller-Strasse 27 T: +49 7071 29 81 94 7 09:30 - 4:30 p.m. 72076 Tübingen www.dzne.de Title Name Country Institution Page Institution Page

Dr. Carmen ABATE Italy Università degli Studi di Bari 15 Biocenter at Ludwig Maximilians University of Munich – LMU 37 Prof. Dr. Yi-Ming CHEN Taiwan National Yang-Ming University 16 Biozentrum der Ludwig-Maximilians-Universtität München – LMU

Dr. Chi-Shiun CHIANG Taiwan National Tsing Hua University 17 BioM Biotech Cluster Development GmbH 38 Dr. Marwan EL SABBAN Lebanon American University of Beirut 18 European Molecular Biology Laboratory – EMBL 58 Prof. Dr. Willy FLEGEL USA National Institutes of Health, 19 Europäisches Laboratorium für Molekularbiologie – EMBL Maryland

Dr. Marc-André FORTIN Canada Université Laval / Centre Hospitalier 20 Fraunhofer Institute for Interfacial Engineering and Biotechnology – IGB 54 de Québec (CHUQ) Fraunhofer-Institut für Grenzﬂ ächen- und Bioverfahrenstechnik – IGB Dr. José A. GONZALEZ Cuba University of Medical Science of 21 Gene Center Munich at Ludwig Maximilians University Munich – LMU 36 HERNANDEZ Havanna Genzentrum der Ludwig-Maximilians-Universität München – LMU Dr. Dennis K. HORE Canada University of Victoria 22

Dr. Baiba JANSONE Latvia University of Latvia 23 German Cancer Research Center – DKFZ 62 Deutsches Krebsforschungszentrum – DKFZ Dr. Michael KOLIOS Canada Ryerson University 24 Index of Institutions (in alphabetical order) Institutions Index Institutions (in alphabetical order) of Participants Index Prof. Dr. Helen LIAPIS USA Washington University School of 25 German Centre for Neurodegenerative Diseases – DZNE 52 70 Medicine Deutsches Zentrum für Neurodegenerative Erkrankungen – DZNE 71 Dr. Anne LUEBKE USA University of Rochester Medical 26 Hertie Institute for Clinical Brain Research – HIH 52 Center Hertie-Institut für klinische Hirnforschung –HIH Dr. Ambika MATHUR USA Wayne State University 27

Prof. Dr. Hala MOHTASEB Lebanon American University of Beirut 28 Institute for Interfacial Engineering – IGVT 54 Instituts für Grenzﬂ ächenverfahrenstechnik – IGVT Dr. Donna MURASKO USA Drexel University 29

Dr. Ceferino OBCEMEA USA Memorial Sloan-Kettering Cancer 30 Max Planck Institute of Biochemistry – MPIB 40 Center Max-Planck-Institut für Biochemie – MPIB Dr. Rima ROZEN Canada McGill University 31 National Center for Tumor Diseases Heidelberg – NCT 62 Dr. Dar-Bin SHIEH Taiwan National Cheng Kung University 32 Nationales Centrum für Tumorerkrankungen Heidelberg – NCT Prof. Dr. Bing-Wen SOONG Taiwan National Yang-Ming University 33 Rinecker Proton Therapy Center – RPTC 44 Prof. Dr. Jack TUSZYNSKI Canada University of Alberta 34 Roche Diagnostics GmbH 46 Dr. Ching TZAO Taiwan National Defense Medical Center 35 Institutions Institutions Notes Notes

72 73 Table of Contents Page

Preface 3

Program 4

Escort 14

Proﬁ le of Participants 15

Proﬁ le of Institutions and Speakers 36

List of Hotels & Restaurants 66

Important Numbers 67

Addresses of Institutions 68

Index of Participants (in alphabetical order) 70

Index of Institutions (in alphabetical order) 71

Notes 72 Table of Content Institutions Table Institutions Notes

74 75 Coordination of the Press Tour and Publisher Photo Credits iStockphoto, Alexander Raths: German Academic Exchange Service (DAAD) Cover | Ludwig Maximilians University of Section 523 – Marketing for Research Munich: p.2, p.36, p.38 | European Kennedyallee 50, 53175 Bonn Molecular Biology Laboratory: p.2, p.58 | www.daad.de Fraunhofer Institute for Interfacial Engineering www.research-in-germany.de and Biotechnology: p.2, p.54 | German Cancer Research Center: p.2, p.62 | Hertie Dr. Christian Schäfer Institute for Clinical Brain Research: p.2 | Head of Section: Internationalisation of Research Max Planck Institute of Biochemistry: p.2, Email: [email protected] p.40 | Rinecker Proton Therapy Center: p.2, p.45 | Roche Diagnostics GmbH: p.2, p.46, Anne Knab p.51 Project Ofﬁ cer, Section: Marketing for Research Email: [email protected]

Organisation MICHEL International Relations & Services Friedrichstrasse 191 10117 Berlin

Rebecka Michel Institutions Email: [email protected] www.michel-irs.com 76

Layout and Typsetting Jonas und der Wolf GbR Email: [email protected] www.jonasundderwolf.de

Print run: 200 - December 2011 Printed by: Europrint Medien GmbH